165 related articles for article (PubMed ID: 26240115)
1. The blocking of angiotensin II type 1 receptor and RhoA/Rho kinase activity in hypertensive patients: Effect of olmesartan medoxomil and implication with cardiovascular-renal remodeling.
Ravarotto V; Pagnin E; Maiolino G; Fragasso A; Carraro G; Rossi B; Calò LA
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1245-50. PubMed ID: 26240115
[TBL] [Abstract][Full Text] [Related]
2. Increased level of p63RhoGEF and RhoA/Rho kinase activity in hypertensive patients.
Calò LA; Davis PA; Pagnin E; Dal Maso L; Maiolino G; Seccia TM; Pessina AC; Rossi GP
J Hypertens; 2014 Feb; 32(2):331-8. PubMed ID: 24356540
[TBL] [Abstract][Full Text] [Related]
3. Effect of olmesartan on oxidative stress in hypertensive patients: mechanistic support to clinical trials derived evidence.
Cal LA; Maso LD; Caielli P; Pagnin E; Fusaro M; Davis PA; Pessina AC
Blood Press; 2011 Dec; 20(6):376-82. PubMed ID: 21504378
[TBL] [Abstract][Full Text] [Related]
4. Gαq/p63RhoGEF interaction in RhoA/Rho kinase signaling: investigation in Gitelman's syndrome and implications with hypertension.
Pagnin E; Ravarotto V; Maiolino G; Naso E; Davis PA; Calò LA
J Endocrinol Invest; 2018 Mar; 41(3):351-356. PubMed ID: 28840514
[TBL] [Abstract][Full Text] [Related]
5. Effect of olmesartan medoxomil on number and survival of circulating endothelial progenitor cells and calcitonin gene related peptide in hypertensive patients.
Calò LA; Dal Maso L; Pagnin E; Ravarotto V; Facco M; Boscaro E; Maiolino G; Pessina AC; Rossi GP
J Hypertens; 2014 Jan; 32(1):193-9. PubMed ID: 24309489
[TBL] [Abstract][Full Text] [Related]
6. Effect of Early Normotension with Olmesartan on Rho-kinase Activity in Hypertensive Patients.
Cantin C; Jalil JE; Bulnes JF; Novoa U; MacNab P; Godoy I; Córdova S; Gabrielli L; Ocaranza MP
Curr Vasc Pharmacol; 2020; 18(1):87-91. PubMed ID: 30663569
[TBL] [Abstract][Full Text] [Related]
7. Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.
Malacco E; Omboni S; Mallion JM; Volpe M;
High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):213-22. PubMed ID: 23430666
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress and the altered reaction to it in Fabry disease: A possible target for cardiovascular-renal remodeling?
Ravarotto V; Carraro G; Pagnin E; Bertoldi G; Simioni F; Maiolino G; Martinato M; Landini L; Davis PA; Calò LA
PLoS One; 2018; 13(9):e0204618. PubMed ID: 30261035
[TBL] [Abstract][Full Text] [Related]
9. Improvement of Plasma Biomarkers after Switching Stroke Patients from Other Angiotensin II Type I Receptor Blockers to Olmesartan.
Tada Y; Yagi K; Uno M; Matsushita N; Kanematsu Y; Kuwayama K; Shimada K; Nishi K; Hirasawa M; Satomi J; Kitazato KT; Kageji T; Matsuura E; Nagahiro S
J Stroke Cerebrovasc Dis; 2015 Jul; 24(7):1487-92. PubMed ID: 25891757
[TBL] [Abstract][Full Text] [Related]
10. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of intrarenal angiotensin II levels in uninephrectomized aldosterone/salt-treated hypertensive rats; renoprotective effects of an ultrahigh dose of olmesartan.
Fan YY; Baba R; Nagai Y; Miyatake A; Hosomi N; Kimura S; Sun GP; Kohno M; Fujita M; Abe Y; Nishiyama A
Hypertens Res; 2006 Mar; 29(3):169-78. PubMed ID: 16755152
[TBL] [Abstract][Full Text] [Related]
12. Mas Receptor Activation Contributes to the Improvement of Nitric Oxide Bioavailability and Vascular Remodeling During Chronic AT1R (Angiotensin Type-1 Receptor) Blockade in Experimental Hypertension.
Savoia C; Arrabito E; Parente R; Nicoletti C; Madaro L; Battistoni A; Filippini A; Steckelings UM; Touyz RM; Volpe M
Hypertension; 2020 Dec; 76(6):1753-1761. PubMed ID: 33070664
[TBL] [Abstract][Full Text] [Related]
13. RhoA/ROCK Pathway Activation is Regulated by AT1 Receptor and Participates in Smooth Muscle Migration and Dedifferentiation via Promoting Actin Cytoskeleton Polymerization.
Qi Y; Liang X; Dai F; Guan H; Sun J; Yao W
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751352
[TBL] [Abstract][Full Text] [Related]
14. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
[TBL] [Abstract][Full Text] [Related]
15. Modulation of AT-1R/CHOP-JNK-Caspase12 pathway by olmesartan treatment attenuates ER stress-induced renal apoptosis in streptozotocin-induced diabetic mice.
Lakshmanan AP; Thandavarayan RA; Palaniyandi SS; Sari FR; Meilei H; Giridharan VV; Soetikno V; Suzuki K; Kodama M; Watanabe K
Eur J Pharm Sci; 2011 Dec; 44(5):627-34. PubMed ID: 22033153
[TBL] [Abstract][Full Text] [Related]
16. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
Mason RP
Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
[TBL] [Abstract][Full Text] [Related]
17. Air pollution exposure potentiates hypertension through reactive oxygen species-mediated activation of Rho/ROCK.
Sun Q; Yue P; Ying Z; Cardounel AJ; Brook RD; Devlin R; Hwang JS; Zweier JL; Chen LC; Rajagopalan S
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1760-6. PubMed ID: 18599801
[TBL] [Abstract][Full Text] [Related]
18. Proinflammatory/profibrotic effects of aldosterone in Gitelman's syndrome, a human model opposite to hypertension.
Ravarotto V; Simioni F; Sabbadin C; Pagnin E; Maiolino G; Armanini D; Calò LA
J Endocrinol Invest; 2019 May; 42(5):521-526. PubMed ID: 30136149
[TBL] [Abstract][Full Text] [Related]
19. Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function.
Albayrak S; Ordu S; Ozhan H; Yazici M; Aydin M; Alemdar R; Kaya A
Blood Press; 2009; 18(4):187-91. PubMed ID: 19521888
[TBL] [Abstract][Full Text] [Related]
20. Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats.
Varagic J; Ahmad S; VonCannon JL; Moniwa N; Brosnihan KB; Wysocki J; Batlle D; Ferrario CM
Am J Hypertens; 2013 May; 26(5):583-90. PubMed ID: 23459599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
